TORONTO, June 7, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (Frankfurt: 8TV) (OTC: AINMF), is pleased to announce that after a successful application process the Company's common shares will begin trading on the OTCBQ® Market (the "OTCQB") at the opening of the market on June 7, 2023, under the stock symbol "AINMF".

The Company believes that the move to the OTCQB will provide enhanced investor benefits including greater access to analyst coverage and news services, broader broker dealers interest and more comprehensive compliance requirements and higher reporting standards than the prior OTC tier.  Historically, companies that have made the move up to the OTCQB tier have experienced increased investor awareness, greater liquidity and visibility of their common stock.

The Company, as previously announced, received Depository Trust & Clearing Corporation ("DTC") eligibility. DTC eligibility allows NetraMark shares to be electronically cleared and settled which streamline the process of trading, enhance liquidity, and provide direct access to investors in the United States (US). DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world's largest securities depositories that manages the electronic clearing and settlement of publicly traded companies.

"Uplisting to the OTCQB represents a significant milestone in the growth of NetraMark. It will enhance our visibility within the US investment community, open the Company to new institutional investors and broaden our shareholder base," said CEO George Achilleos.

NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the benefits of the uplisting to the OTCQB and obtaining DTC eligibility including greater access to analyst coverage and news services, broader broker dealers interest, more comprehensive compliance requirements and higher reporting standards than the prior OTC tier, increased investor awareness, greater liquidity and visibility within the US investment community, broadening our shareholder base, opening the Company to institutional investors and more streamlined trading process which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events.  Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.  Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.  The forward-looking statements are expectations only and are subject to known and unknown, risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements.  Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.  New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR atwww.sedar.com including our Management's Discussion and Analysis for the year ended September 30, 2022.  These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.